Cargando…
Menogaril, an Anthracycline Compound with a Novel Mechanism of Action: Cellular Pharmacology
Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanism of action has not been clarified yet. This study revealed that its cytotoxicity correlated very well with the inhibit...
Autores principales: | Wierzba, Konstanty, Sugimoto, Yoshikazu, Matsuo, Ken‐ichi, Toko, Toshiyuki, Takeda, Setsuo, Yamada, Yuji, Tsukagoshi, Shigeru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918082/ https://www.ncbi.nlm.nih.gov/pubmed/2144516 http://dx.doi.org/10.1111/j.1349-7006.1990.tb02654.x |
Ejemplares similares
-
Menogaril, an Anthracycline Derivative, Inhibits DNA Topoisomerase II by Stabilizing Cleavable Complexes
por: Ono, Katsuhiro, et al.
Publicado: (1992) -
P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.
por: Badiner, G. J., et al.
Publicado: (1990) -
Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines
por: Aoyagi, Yoshimi, et al.
Publicado: (2000) -
A Potential Use of a Synthetic Retinoid TAC‐101 as an Orally Active Agent That Blocks Angiogenesis in Liver Metastases of Human Stomach Cancer Cells
por: Oikawa, Tsutomu, et al.
Publicado: (2001) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)